Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

On Aug 23, Zacks Investment Research downgraded Patterson Companies (PDCO - Analyst Report) to a Zacks Rank #3 (Hold) from Zacks Rank #2 (Buy) on the heels of a disappointing first-quarter fiscal 2014 results.

Why the Downgrade?

Patterson reported a disappointing fiscal 2014 first quarter results, reflecting a challenging macro environment. The company delivered negative earnings surprises in 3 out of the last 4 quarters with a negative average surprise of 6.03%.

Patterson’s first-quarter fiscal 2014 earnings per share (EPS) of 45 cents per share was flat year over year and missed the Zacks Consensus Estimate by 3 cents. The company’s planned investment in IT lowered EPS by a cent. In the reported quarter, net income declined 3.4% to $45.9 million from $47.5 million in the year-ago period.

Moreover, revenues for the quarter dropped marginally by 1% to $880.1 million from $889.2 million reported in the first quarter of fiscal 2014. Revenues were considerably lower than the Zacks Consensus Estimate of $918 million.

Revenues from the core Patterson Dental declined 2.3% mainly due to an 11.7% drop in sales of the equipment and software offerings. However, management asserts that the dental equipment business faced difficult year-over-year comparisons and is confident that the business will deliver incremental returns for the rest of fiscal 2014 on the back of new products and rising demand.

PDCO’s margins too remained under pressure in the reported quarter. Moreover, despite its long-term benefits, the decision to divest certain non-core products from the Patterson Medical unit is likely to accelerate operating expenses in the near-term.

Despite these shortcomings, we note that the Veterinary business grew modestly in the quarter, reflecting a tailwind in the underlying market. Moreover, the Medical business is geared to grow in the long-term on the back of its advanced products portfolio as well as underlying favorable demographics.

Other Stocks to Consider

Other medical stocks that are worth considering include MWI Veterinary Supply (MWIV - Analyst Report), Align Technology (ALGN - Analyst Report) and The Cooper Companies (COO - Analyst Report). All these stocks carry a Zacks Rank #2 (Buy).
 

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GRP IN DXYN 15.84 +7.90%
BOFI HLDG IN BOFI 85.30 +4.97%
RAMBUS INC RMBS 12.31 +4.41%
VIPSHOP HOLD VIPS 148.73 +4.35%
NETFLIX INC NFLX 345.74 +4.32%